Generic Savella Availability

Savella is a brand name of milnacipran, approved by the FDA in the following formulation(s):

SAVELLA (milnacipran hydrochloride - tablet;oral)

  • Manufacturer: CYPRESS BIOSCIENCE
    Approval date: January 14, 2009
    Strength(s): 12.5MG, 25MG, 50MG [RLD], 100MG

Has a generic version of Savella been approved?

No. There is currently no therapeutically equivalent version of Savella available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Savella. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods of treating fibromyalgia
    Patent 6,602,911
    Issued: August 5, 2003
    Inventor(s): Jay D.; Kranzler & Srinivas G.; Rao
    Assignee(s): Cypress Bioscience, Inc.
    The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
    Patent expiration dates:
    • January 14, 2023
      ✓ 
      Patent use: MANAGEMENT OF FIBROMYALGIA (FM)
  • Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
    Patent 6,992,110
    Issued: January 31, 2006
    Inventor(s): Kranzler; Jay D. & Rao; Srinivas G.
    Assignee(s): Cypress Bioscience, Inc.
    The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
    Patent expiration dates:
    • November 5, 2021
      ✓ 
      Patent use: MANAGEMENT OF FIBROMYALGIA (FM)
  • Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
    Patent 7,888,342
    Issued: February 15, 2011
    Inventor(s): Kranzler; Jay D. & Rao; Srinivas G.
    Assignee(s): Cypress Bioscience, Inc.
    The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
    Patent expiration dates:
    • November 5, 2021
      ✓ 
      Patent use: MANAGEMENT OF FIBROMYALGIA (FM)
  • Milnacipran for the long-term treatment of fibromyalgia syndrome
    Patent 7,994,220
    Issued: August 9, 2011
    Inventor(s): Rao; Srinivas G. & Gendreau; Michael & Kranzler; Jay D.
    Assignee(s): Cypress Bioscience, Inc.
    The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.
    Patent expiration dates:
    • September 19, 2029
      ✓ 
      Patent use: MANAGEMENT OF FIBROMYALGIA

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 14, 2014 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)